Clinical Trials
10 trialsNCT03670966 2026-05-04
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT01203722 2026-02-19
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00429143 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
Thomas Jefferson University
Phase 1/2 Completed
NCT01664910 2024-07-23
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02145403 2022-01-03
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT00429416 2016-11-29
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Thomas Jefferson University
Phase 1/2 Completed
NCT00058825 2016-11-07
HIMSUM
Baylor College of Medicine
Phase 1/2 Terminated
NCT00810602 2014-04-11
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT00369226 2013-07-25
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00056966 2012-06-29
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Baylor College of Medicine
Phase 1/2 Completed